ID   CCRF/CEM/ara-C/D
AC   CVCL_A5TZ
SY   CEM/ara-C/D
DR   Wikidata; Q107114624
RX   PubMed=10769646;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from sampling site: Peripheral blood. Cell type=T-cell.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 23-06-22; Version: 3
//
RX   PubMed=10769646;
RA   Martin-Aragon S., Mukherjee S.K., Taylor B.J., Ivy S.P., Fu C.H.,
RA   Ardi V.C., Avramis V.I.;
RT   "Cytosine arabinoside (ara-C) resistance confers cross-resistance or
RT   collateral sensitivity to other classes of anti-leukemic drugs.";
RL   Anticancer Res. 20:139-150(2000).
//